Search Results - "D.V.T. Catenacci"

Assessment of the impact of FcγRIIIA single-nucleotide polymorphisms on the efficacy of IgG1 monoclonal antibodies in patients with advanced gastroesophageal adenocarcinoma by A.V. Serritella, N.K.S. Grewal, B. Peterson, K. Arndt, D.D. Gaudio, P. Liu, A. Shergill, B. Polite, H.L. Kindler, D.V.T. Catenacci, C.Y. Liao

“…Background: Immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), such as trastuzumab and ramucirumab, are utilized in advanced gastroesophageal…”
Get full text

483 Development of a Quantitative Colorectal Cancer SRM Assay for Use in FFPE Tumor Tissues by Hembrough, T, Henderson, L, Xu, P, Liao, W.L, Burrows, J, Catenacci, D.V.T

Get full text

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer by Berchuck, J.E., Facchinetti, F., DiToro, D.F., Baiev, I., Majeed, U., Reyes, S., Chen, C., Zhang, K., Sharman, R., Uson Junior, P.L.S., Maurer, J., Shroff, R.T., Pritchard, C.C., Wu, M.-J., Catenacci, D.V.T., Javle, M., Friboulet, L., Hollebecque, A., Bardeesy, N., Zhu, A.X., Lennerz, J.K., Tan, B., Borad, M., Parikh, A.R., Kiedrowski, L.A., Kelley, R.K., Mody, K., Juric, D., Goyal, L.

“…Targeted therapies have transformed clinical management of advanced biliary tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for…”
Get full text

Tackling diversity within diversity by Lomnicki, S., Setia, N., Catenacci, D.V.T.

Get full text

Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations by Hollebecque, A., Borad, M., Sahai, V., Catenacci, D.V.T., Murphy, A., Vaccaro, G., Paulson, A., Oh, D.-Y., Féliz, L., Lihou, C., Zhen, H., Abou-Alfa, G.K.

Get full text

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment by An, E., Ock, C.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., Kim, T.-Y., Liao, W.-L., Cecchi, F., Blackler, A., Thyparambil, S., Kim, W.H., Burrows, J., Hembrough, T., Catenacci, D.V.T., Oh, D.-Y., Bang, Y.-J.

“…A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC…”
Get full text

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A by Catenacci, D.V.T., Kang, Y.-K., Yoon, H.H., Shim, B.Y., Kim, S.T., Oh, D.-Y., Spira, A.I., Ulahannan, S.V., Avery, E.J., Boland, P.M., Chao, J., Chung, H.C., Gardner, F., Klempner, S.J., Lee, K.-W., Oh, S.C., Peguero, J., Sonbol, M.B., Shen, L., Moehler, M., Sun, J., Li, D., Rosales, M.K., Park, H.

“…Human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric and gastroesophageal adenocarcinoma (GEA) is globally treated with chemotherapy…”
Get full text

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA) by Catenacci, D.V.T., Park, H., Uronis, H.E., Kang, Y.-K., Ng, M., Gold, P., Lacy, J., Enzinger, P.C., Park, S., Lee, K.-W., Yen, J., Odegaard, J., Franovic, A., Baughman, J., Muth, J., Wynter-Horton, A., Wu, T., Wigginton, J., Davidson-Moncada, J.K., Bang, Y.-J.

Get full text

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO) by Evelhoch, J.L., Mogg, R., Cristescu, R., Aurora-Garg, D., Chow, L.Q., Loi, S., Catenacci, D.V.T., Matulonis, U.A., Ott, P.A., Antonarakis, E.S., Poehlein, C.H., Joe, A., Keefe, S.M., Kang, P., Karantza, V., Cheng, J., Rubin, E.H.

Get full text

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma by Catenacci, D.V.T., Chung, H.C., Shen, L., Moehler, M., Yoon, H.H., Rosales, M.K., Kang, Y.-K.

“…Since completion of the Trastuzumab for Gastric Cancer study, trastuzumab with doublet chemotherapy (a fluoropyrimidine and a platinum) has been the…”
Get full text

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study by Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.

“…Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ) is an aggressive disease with poor prognosis. In the TAGS study,…”
Get full text

A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Gastric Cancer by Muro, K., Bang, Y., Shankaran, V., Geva, R., Catenacci, D.V.T., Gupta, S., Eder, J.P., Berger, R., Gonzalez, E.J., Pulini, J., Ray, A.B., Dolled-Filhart, M., Emancipator, K., Pathiraja, K., Shu, X., Koshiji, M.R., Cheng, J., Chung, H.C.

Get full text

LBA15A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER by Muro, K., Bang, Y., Shankaran, V., Geva, R., Catenacci, D.V.T., Gupta, S., Eder, J.P., Berger, R., Gonzalez, E.J., Pulini, J., Ray, A.B., Dolled-Filhart, M., Emancipator, K., Pathiraja, K., Shu, X., Koshiji, M.R., Cheng, J., Chung, H.C.

“…Abstract Aim: The PD-1 receptor-ligand pathway can be used by tumors to evade immune surveillance, thereby allowing neoplastic growth. Pembro is a highly…”
Get full text